COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Surgicel® (Fibrillar) in Non-variceal UGI Bleeding

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02054260
Recruitment Status : Unknown
Verified November 2014 by Su Jin Hong, Soonchunhyang University Hospital.
Recruitment status was:  Recruiting
First Posted : February 4, 2014
Last Update Posted : November 19, 2014
Information provided by (Responsible Party):
Su Jin Hong, Soonchunhyang University Hospital

Brief Summary:
The aim of this study is to assess of effect of Surgicel® (Fibrillar) for preventing delayed bleeding after endoscopic hemostasis in non-variceal upper gastrointestinal bleeding

Condition or disease Intervention/treatment Phase
Non-variceal Upper Gastrointestinal Bleeding Drug: Surgicel Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Primary Completion Date : December 2015

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Surgicel add therapy Drug: Surgicel

Primary Outcome Measures :
  1. Rebleeding rate at the second look endoscopy [ Time Frame: 2 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patients with non variceal upper gastrointestinal bleeding proven by esophagogastroduodenoscopy
  • Patients with active bleeding (Forrest classification Ia or Ib or IIa)

Exclusion Criteria:

  • Patients with upper gastrointestinal tract malignancy
  • Patients with acute severe illness
  • Coagulopathy: liver cirrhosis, thrombocytopenia
  • Pregnant women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02054260

Layout table for location contacts
Contact: Su Jin Hong, MD, PhD +82-32-621-5087

Layout table for location information
Korea, Republic of
Digestive Disease Center and Research Institute, Department of Internal Medicine, Soonchunhyang University College of Medicine Recruiting
Bucheon, Korea, Republic of, 420-767
Contact: Su Jin Hong, MD, PhD    +82-32-621-5087   
Sponsors and Collaborators
Soonchunhyang University Hospital

Layout table for additonal information
Responsible Party: Su Jin Hong, Professor, Soonchunhyang University Hospital Identifier: NCT02054260    
Other Study ID Numbers: SCHBC_IRB_2013-40
First Posted: February 4, 2014    Key Record Dates
Last Update Posted: November 19, 2014
Last Verified: November 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastrointestinal Hemorrhage
Pathologic Processes
Gastrointestinal Diseases
Digestive System Diseases